Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel
NASDAQ:NBTX

Nanobiotix H1 2026 Earnings Report

Nanobiotix logo
$33.46 -1.78 (-5.05%)
Closing price 04:00 PM Eastern
Extended Trading
$33.38 -0.09 (-0.25%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanobiotix EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Nanobiotix Revenue Results

Actual Revenue
$3.17 million
Expected Revenue
$1.73 million
Beat/Miss
Beat by +$1.44 million
YoY Revenue Growth
N/A

Nanobiotix Announcement Details

Quarter
H1 2026
Date
9/24/2026
Time
After Market Closes
Conference Call Date
Thursday, September 24, 2026
Conference Call Time
4:15PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Nanobiotix's H1 2026 Press ReleasePress Release

Nanobiotix Earnings Headlines

NANOBIOTIX Provides First Half 2026 Operational and Financial Update
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368753/0/en/nanobiotix-provides-first-half-2026-operational-and-financial-update.html
Voting Rights and Shares Capital of the Company
September 22 at 4:15 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366889/0/en/voting-rights-and-shares-capital-of-the-company.html
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel
September 24 at 1:00 AM  |  Digest Publishing (Ad)
Nanobiotix (NBTX) Projected to Announce Quarterly Earnings on Tuesday
September 22 at 1:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037820
Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Given Consensus Rating of "Moderate Buy" by Brokerages
September 21 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036472
Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nanobiotix-nbtx-lung-tumor-control-170648699.html
See More Nanobiotix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email.

About Nanobiotix

Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles. NBTXR3 is injected directly into a tumor and activated by standard radiotherapy. Nanobiotix has evaluated the candidate in several solid-tumor settings and is studying its potential for use in combination with other cancer treatments, including immunotherapies. NBTXR3 has not been approved for commercial use by regulatory authorities.

Founded in 2003, Nanobiotix is headquartered in Paris, France, and has conducted development activities and clinical studies in multiple geographic regions, including Europe, the United States and Asia. The company was co-founded by Laurent Levy, who has served as its chief executive officer and has led its development of nanoparticle-based oncology treatments.

View Nanobiotix Profile
Earnings Tools